Signal detection for vaccine side effects that have not been specified in advance
暂无分享,去创建一个
[1] J. Avorn,et al. High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.
[2] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[3] George Hripcsak,et al. Mining a clinical data warehouse to discover disease-finding associations using co-occurrence statistics , 2005, AMIA.
[4] Carolyn C Cannuscio,et al. Cardiovascular risk of selective cyclooxygenase‐2 inhibitors and other non‐aspirin non‐steroidal anti‐inflammatory medications , 2006, Pharmacoepidemiology and drug safety.
[5] C Michael Stein,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.
[6] M. Kulldorff,et al. A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance , 2011 .
[7] R. Thompson,et al. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. , 1987, American journal of public health.
[8] Richard Platt,et al. Active Influenza Vaccine Safety Surveillance: Potential Within a Healthcare Claims Environment , 2009, Medical care.
[9] A. M. Walker. Pattern recognition in health insurance claims databases , 2001, Pharmacoepidemiology and drug safety.
[10] George Hripcsak,et al. A statistical methodology for analyzing co-occurrence data from a large sample , 2007, J. Biomed. Informatics.
[11] C. Meschievitz,et al. Efficacy of a two-component acellular pertussis vaccine in infants. , 1997, The Pediatric infectious disease journal.
[12] A. Buist,et al. Asthma drug use and the development of Churg–Strauss syndrome (CSS) , 2007, Pharmacoepidemiology and drug safety.
[13] R. O’Neill,et al. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.
[14] A. M. Walker,et al. Precautions for proactive surveillance , 2002, Pharmacoepidemiology and drug safety.
[15] M. Kulldorff,et al. Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.
[16] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[17] Robert L Davis,et al. Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.
[18] Richard Beasley,et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. , 2004, Clinical therapeutics.
[19] George Hripcsak,et al. Use abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases , 2008, J. Biomed. Informatics.
[20] P. Diaconis,et al. Testing for independence in a two-way table , 1985 .
[21] David Madigan,et al. Influence of the MedDRA® hierarchy on pharmacovigilance data mining results , 2009, Int. J. Medical Informatics.
[22] M. Braun,et al. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. , 2001, Vaccine.